In June 2023, the U.S. Food and Drug Administration (FDA) rolled out final guidance on administering risk and efficacy details for direct-to-consumer (DTC) promotional labelling and advertisements for prescription drug and biologic products for humans and drug products for animals.
The guidance was provided to ensure the responsible provision of risk and benefit information in DTC promotional materials, focusing extensively on the quantified display of these elements. The new norms stem from the FDA’s concerns on how the current practice of solely qualitative presentation of risks can mislead consumers, leading to their misunderstanding or downplaying of potential health threats.
Furthermore, the FDA highly encouraged the application of quantitative efficacy claims. This is to promote improved understanding for consumers whereby hard numbers and percentages provide a more concrete understanding of benefits than mere qualitative statements.
This final guidance erected by the FDA highlights its intention to make sure that consumers are being satisfactorily informed about the risks and utilities of pharmaceuticals. These rulings not only provide a concrete roadmap for pharmaceutical companies on how to present risk and efficacy details in their promotional materials but also work towards enhancing patient understanding and facilitating informed choices regarding the use of prescription drugs and biological products.
You can read in detail about this update
here.